Huons USA promotes drug portfolio and novel pipelines at CPHI Americas

Huons USA, the U.S. sales division of Korean pharmaceutical group Huons, actively promoted the company's existing drug products and innovative research pipelines at the Convention on Pharmaceutical Ingredients Americas (CPHI Americas), held at the Pennsylvania Convention Center in Philadelphia from May 20 to 22. 

The international pharmaceutical trade show attracted thousands of attendees, including representatives from over 500 pharmaceutical companies, distributors, and R&D sectors spanning more than 50 countries.

During the event, Huons USA highlighted a range of products and pipelines from Huons and its subsidiaries Huonslab and Pangen Biotech.

A key focus for Huons USA was the promotion of Huons' established injectable medications and ophthalmic solutions. Notably, the company showcased its recently FDA-approved 1% and 2% 2mL multi-dose vials of lidocaine hydrochloride injection, which garnered significant attention at the convention.

Furthermore, Huons USA introduced Pangen Biotech's biosimilar of Erythropoietin (EPO) and also promoted its contract development and manufacturing organization (CDMO) services offered for biopharmaceutical companies.

Huonslab's proprietary platform technology, known as HyDIFFUZE, was also a point of emphasis for Huons USA. This technology utilizes recombinant human natural hyaluronidase to enable the conversion of intravenous (IV) drug administration to subcutaneous (SC) injection.

Choi Jae-myung, CEO of Huons USA, said, “We focused on raising Huons Group’s global presence and promoting brand competitiveness at CPHI Americas. We plan to engage in further discussions with buyers and distributors at the convention for exploring new business cooperation and export opportunities.”